Patient Test Result Report

Patient Name: Mengshi Lin	**Collection Date:** Jan. 27, 2021	**Specimen Type:** Nasopharyngeal Swab
DOB: 06/03/1996	**Processing Date:** Jan. 20, 2021	**Test Type:** SARS-CoV-2, NAA RT-PCR Test
Sex: Female	**Location:** Mobile Lab	

TEST	RESULT	INTERPRETATION
SARS-CoV-2, NAA RT-PCR Test	**DETECTED***	SARS-CoV-2 was detected in your sample.**

* SARS-Cov-2 is considered a notifiable condition under Washington Administrative Code (WAC) 246-101, Notifiable Conditions. Results for COVID-19 testing will be reported to the Washington State Department of Health as required by law.
**Refer to the attached FDA Fact Sheet for Patients included with this report for more information regarding testing, intended use and interpretation of results. For further questions regarding this result, consultation with your primary care physician is recommended.

1. An anterior nares or mid-turbinate specimen collected by a healthcare professional or self-collected by the patient is acceptable when the patient is in an appropriate clinical setting or under appropriate observation.

2. This test is not yet approved or cleared by the United States FDA. When there are no FDA-approved or cleared tests available, and other criteria are met, FDA can make tests available under an emergency access mechanism called an Emergency Use Authorization (EUA), for use in authorized laboratories. The EUA for this test is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19. This EUA will remain in effect for the duration of the COVID-19 declaration justifying emergency of IVDs, under Section 564(b)(1) of the Act 21, U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

FidaLab Reference Laboratory: Methods and Limitations

Method: Multiplex real-time RT-PCR test intended for the presumptive qualitative detection of nucleic acid from SARS-CoV-2.

Disclaimer: FidaLab implements safeguards to avoid technical errors throughout the testing process. FidaLab is not responsible for errors in specimen collection, transportation, and/or other errors made prior to receipt at our laboratory.

FidaLab Medical Director

Michael Kalnoski, MD

FIDALAB
2296 W. Commodore Way, Suite 220 | Seattle, WA 98199
Tel: (425)559-0680
Fax: (425)732-4433
Michael Kalnoski, MD | Medical Director